Intracellular iron, essential for cancer cell proliferation and metabolism, is modified in cancer cells. Triple-negative breast cancers are metastatic cancers associated with a high recurrence rate, poor prognosis and lack of effective targeted therapies. We are investigating the potential of Deferiprone, a clinically approved intracellular iron chelator for non-cancer related diseases, to improve chemotherapeutic treatment response in triple-negative breast cancer by altering iron-dependent proliferation and metabolism. The effectiveness of Deferiprone to impair triple-negative breast cancer cell growth and affect cellular metabolism was evaluated by monitoring live cells, exposed to Deferiprone, in an MR-compatible cell bioreactor using multi-nuclear MRS.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords